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Activated Ras utilises several downstream pathways, including the mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK
pathway and the phosphoinositide 3-kinase (PI-3k)/Akt pathway, to promote cell proliferation and to inhibit apoptosis. To investigate
which pathway plays a major role in Ras-induced drug resistance to chemotherapeutic agents in breast cancer cells, we transfected
MCF7 breast cancer cells with a constitutively active H-RasG12V and examined the toxicities of three commonly used breast cancer
chemotherapeutic agents, paclitaxel, doxorubicin, and 5-fluorouracil in these cells under the conditions that PI-3K or MEK were
selectively inhibited by their respective specific inhibitors or dominant negative expression vectors. We found that Ras-mediated drug
resistance is well correlated with resistance to apoptosis induced by anticancer agents in MCF7 breast cancer cells. Although inhibition
of MEK/MAPK or PI-3K/Akt can each enhance the cytotoxicity of paclitaxel, doxorubicin, or 5-fluorouracil, inhibition of the PI-3K/Akt
pathway seems to have a greater effect than inhibition of the MEK/MAPK pathway in reversing Ras-mediated drug resistance. Our
results indicate that the PI-3K pathway may play a more important role in receptor tyrosine kinase-mediated resistance to
chemotherapy and suggest that PI-3K/Akt might be a critical target molecule for anticancer intervention in breast cancer.
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It has been well-demonstrated that chemotherapy is effective in
prolonging both disease-free and overall survival of women with
breast cancer. A further question is how to improve the existing
regimens of breast cancer chemotherapy for better therapeutic
outcomes. Recent studies have provided convincing evidence that
the therapeutic outcome of chemotherapy may be affected by the
expression and activity of receptor tyrosine kinases such as
epidermal growth factor (EGF) receptor, HER2, and their related
molecules. Pursuance of this concept may provide important clues
for optimising the clinical applications of breast cancer che-
motherapy, and for designing new therapeutic approaches.
Members of the Ras superfamily of GTPases act as important
molecular switches to coordinate extracellular stimuli with
activation of intracellular signalling pathways for appropriate
biological responses. Although Ras genetic mutational activation is
infrequent in breast cancer, Ras is often pathologically activated in
breast cancer due to its link to the EGF receptor family or other
tyrosine kinases that signal through Ras and that are commonly
overexpressed in this disease (Kroll et al, 2002). Activated Ras
status has been associated with reduced oestrogen dependence
and increased invasiveness of breast cancer (Kasid et al, 1985;
Sukumar et al, 1988; Sommers et al, 1990). Owing to this important
role of Ras in tumorigenesis, the Ras-signalling pathway has
attracted considerable attention as a target for anticancer therapy.
Novel cancer therapeutic approaches based on the inhibition of
Ras-mediated signalling, including inhibition of Ras processing,
inhibition of Ras protein synthesis, and blockage of downstream
Ras effectors, are being evaluated (Adjei, 2001).
Activated Ras is involved not only in tumour progression but
also possibly in the development of resistance of tumour cells to
chemotherapy and to ionising radiation. While the role of Ras in
mediating resistance to radiation has been relatively well-studied
and is noncontroversial (Gupta et al, 2001), the exact role of Ras in
mediating resistance to various chemotherapeutic agents is
relatively less documented, and in fact, remains controversial or
even paradoxical. Constitutive expression of the H-Ras oncogene
inhibits doxorubicin-induced apoptosis in a rat rhabdomyosarco-
ma cell line (Nooter et al, 1995). In contrast, the expression of
RasG12V in FR3T3 rat fibroblasts sensitised the cells to treatment
with cisplatin (Viktorsson et al, 2000). Similarly, another recent
study found that, in the absence of multidrug resistance, human
tumour cell lines with activated Ras oncogenes were uniformly
more sensitive to most topoisomerase II inhibitors than were cell
lines containing wild-type Ras alleles (Koo et al, 1999).
In the setting of human breast cancer, the mechanisms of drug
resistance associated with advanced or metastatic hormone-
independent breast carcinoma are not yet fully understood. The
human breast carcinoma MCF7 cell line represents a typical in
vitro model of breast cancer with positive oestrogen receptors; the
original MCF7 cells are hormone-dependent and noninvasive and
become hormone-independent and invasive when these cells are
transformed with an activated Ras oncoprotein (Kasid et al, 1985;
Sukumar et al, 1988; Sommers et al, 1990). In the present study, we
investigated the development of drug resistance in MCF7 cells
associated with the expression of an activated Ras (RasG12V) in
these cells. As expected, the expression of RasG12V in MCF7 cells
improved the survival of MCF7 cells in a hormone-depleted culture
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smedium. We found that, compared with control-vector-transfected
cells, the MCF7RasG12V cells exhibited increased resistance to
several chemotherapeutic agents currently used for treating breast
cancer patients. We further compared the role of two well-known
Ras downstream pathways, the PI-3K/Akt pathway and the MAPK/
ERK kinase (MEK)/MAPK pathway, in drug resistance mediated
by activated Ras. The results of our current study provide further
evidence for targeting growth factor receptor and Ras-mediated
signal transduction as an approach for enhancing the therapeutic
outcome of current breast cancer chemotherapy.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies directed against total Akt, ser473-phosphorylated Akt1,
and thr202-phosphorylated MAPK (p42/p44) were obtained from
Cell Signaling Technology, Inc. (Beverly, MA, USA), anti-Ras
antibody was from BD Bioscience Transduction Laboratory (San
Jose, CA, USA), anti-MAPK (Erk2) antibody was from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA), anti-His G antibody
and anti-HA antibody were from Roche Diagnostics Corp
(Indianapolis, IN, USA), and LY294002 and PD98059 were
obtained from CalBiochem Corp. (San Diego, CA, USA). The
antineoplastic agents used in this study were paclitaxel (Taxol)
(Bristol Laboratories, Princeton, NJ, USA), doxorubicin (Adria-
mycin) (Gensia Sicor Pharmaceuticals, Irvine, CA, USA), and 5-
fluorouracil (Adrucil) (Pharmacia, Kalamazoo, MI, USA). All other
reagents were purchased from Sigma Chemical Co. (St Louis, MO,
USA) unless otherwise specified.
Cells, cell culture, and transfection
MCF7 human breast cancer cells were obtained from American
Type Culture Collection (Manassas, VA, USA). The cells were
grown and routinely maintained in Dulbecco’s modified Eagle’s
medium/F12 medium supplemented with 10% foetal bovine serum
(FBS), 2mM glutamine, 100Uml
 1 penicillin, and 100mgml
 1
streptomycin. Cells were incubated at 371C with 5% CO2 and 95%
air.
The RasG12V cDNA (pSRa-H-RasV12, which was kindly
provided by Dr Richard AJ Janssen), was subcloned into pcDNA3.1
expression vector (Invitrogen, Carlsbad, CA, USA). pcDNA3.1
RasG12V or pcDNA3.1 backbone vector was transfected into MCF7
cells with the Fugene-6 transfection kit (Roche Diagnostics),
followed by selection with a medium containing 1000mgml
 1
neomycin (G418), and maintenance in medium containing
400mgml
 1 G418. Stable clones were evaluated for his-tag
expression by Western blot analysis with anti-His G antibodies,
or anti-Ras antibodies.
Cell proliferation assay was performed by seeding cells onto six-
well tissue culture plates at a density of 2 10
4 cellswell
 1,
followed by a 5-day culture in medium supplemented with FBS (10
or 0.5%) or charcoal-stripped (CS) FBS (10 or 0.5%). Cells were
counted with a Coulter counter (Coulter Corp., Miami, FL, USA).
Western blot analysis
Cells were lysed in a lysis buffer containing 50mM Tris, pH 7.4,
150mM NaCl, 0.5% NP-40, 50mM NaF, 1mM Na3VO4,1 m M
phenylmethylsulphonyl fluoride, 25mgml
 1 leupeptin, and
25mgml
 1 aprotinin. The lysates were cleared by centrifugation,
and the supernatants were collected. Equal amounts of lysate
protein were used for the Western blot analyses with the indicated
antibodies (Fan et al, 1995). Specific signals were visualised using
the enhanced chemoluminescence (ECL) detection kit (Amersham,
Arlington Heights, IL, USA).
Chemotherapy cytotoxicity assay
Cells were seeded onto 24-well culture plates. After a 4-h pulse
exposure of the cells to various doses of chemotherapeutic agents,
the cells were cultured for an additional 7 days with drug-free
medium containing 10% CS-PBS. Cell viability was then assessed
by adding 50mlo f1 0m gm l
 1 MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) (Sigma) to 0.5ml of culture
medium and incubating the cells for 3h at 371Ci naC O 2
incubator, followed by cell lysis with 500ml of lysis buffer
containing 20% sodium dodecyl sulphate (SDS) in dimethyl
formamide/H2O( 1 : 1 ,v v
 1), pH 4.7, at 371C for more than 6h.
Cell viability was then determined by measuring the optical
absorbance of cell lysates at a wavelength of 595nm and
normalising the value with the value of the corresponding control
(untreated cells).
Quantification of apoptosis by enzyme-linked
immunosorbent assay (ELISA)
An apoptosis ELISA kit (Roche Diagnostics) was used to
quantitatively measure cytoplasmic histone-associated DNA frag-
ments (mononucleosomes and oligonucleosomes) after induced
cell death. This photomeric enzyme immunoassay was performed
exactly according to the manufacturer’s instructions.
Terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-X nick end labelling (TUNEL) assay
The TUNEL assay was performed as described previously (Liu et al,
2000). Briefly, following fixation with 1% paraformaldehyde on ice
for 1h, the cells were washed once with PBS and then postfixed in
ice-cold 70% ethanol overnight. The next day, the cells were
washed once with PBS before incubation with 50ml of TdT reaction
solution containing 5U of TdT, 0.5nmol of biotin-dUTP, and
2.5mM CoCl2 in TdT buffer (Roche Diagnostics) at 371C for 1h.
After the reaction, the cells were stained with a buffer containing
2.5mgml
 1 FITC-avidin, 0.1% Triton X-100, 5% dried low fat milk
in 4  SSC (0.6 M sodium chloride-60mM sodium citrate, pH 7) in
the dark at room temperature for 1h. Before flow cytometric
analysis (FCM) with a FACScan flow cytometer (Becton Dickinson,
San Jose, CA, USA), the cells were counterstained with a solution
containing 5mgml
 1 propidium iodide and 10mgml
 1 RNase A in
PBS. The FITC signal was analysed using Epics Elite software
(Coulter Corp.).
RESULTS
Characterisation of MCF7 breast cancer cells expressing an
activated Ras
We transfected MCF7 cells with a constitutively active Ras
(RasG12V) expression vector and selected the tranfectants with
400mgml
 1 G418 for positive clones. Over 10 clones expressing
various levels of RasG12V were obtained. Four representative
clones with the highest levels of RasG12V expression are shown in
Figure 1A (gels a and b). Compared with parental or control-
vector-transfected MCF7 cells, the MCF7RasG12V cells exhibited
marked increases in the levels of phosphorylated Akt and MAPK
(Figure 1A gels c and e), indicating that the transfected RasG12V
was functionally constitutively active. The increases in the
activation of Akt and MAPK were not accompanied by changes
in their individual protein levels (Figure 1A gels d and f). While
there was no significant difference in the proliferation rate between
the RasG12V-transfected cells and control-vector-transfected cells
growing in a regular culture medium (Figure 1B), expression of the
RasG12V enhanced the survival of the cells cultured in a low-
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Figure 1 Establishment and characterisation of MCF7 human breast cancer cells expressing constitutively active RasG12V. (A) Parental MCF7 cells,
control-vector-transfected MCF7 cells, and four selected MCF7 cell clones expressing RasG12V were cultured overnight in a medium containing 0.5%
charcoal-stripped fetal bovine serum (CS-FBS). The cells were then harvested for Western blot analyses with various indicated antibodies. (B–E) The cells
described in (A) were cultured for 5 days in a medium containing 10 or 0.5% fetal bovine serum (FBS) (B, C) or 10 or 0.5% CS FBS. Cells were counted with
a Coulter counter.
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Figure 2 Increased resistance of MCF7RasG12V breast cancer cells to treatment with doxorubicin, paclitaxel, and 5-fluorouracil. (A) The cells described
in Figure 1 were pulse-exposed to doxorubicin, paclitaxel, or 5-fluorouracil for 4h at the indicated concentrations. The cells were then cultured fora n
additional 7 days with a drug-free medium supplemented with 10% CS-FBS medium. Cell viabilities after chemotherapy were determined by an MTT assay
as described in Materials and Methods and were expressed as the percentage of the value of untreated cells. (B) One representative cell clone (clone C)
was treated with doxorubicin, paclitaxel, or 5-fluorouracil for 8h, followed by additional culture for 16h with 10% CS-FBS medium. Cells were harvested and
subjected to apoptosis ELISA.
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sserum medium (Figure 1C) or in medium with CS serum
(hormone-depleted) (Figure 1D and E).
Resistance of MCF7RasG12V cells to doxorubicin,
paclitaxel, and 5-fluorouracil (5-FU)
Compared with control-vector-transfected MCF7 cells,
MCF7RasG12V clones showed increased resistance to the treat-
ment with doxorubicin, paclitaxel, or 5-fluorouracil (Figure 2A).
The IC50 of doxorubicin and paclitaxel increased approximately
10-fold, with a lesser increase in the IC50 of 5-fluorouracil. The
increased resistance to each of the individual drugs was associated
with reduced induction of apoptosis by the antineoplastic agents,
assayed by an apoptosis ELISA (Figure 2B).
Involvement of PI-3K and MEK/MAPK in Ras-mediated
drug resistance
We then arbitrarily selected the MCF7RasG12V clone (clone C)
and investigated the potential roles of the two major Ras
downstream pathways, PI3K/Akt and MEK/MAPK, in Ras-
mediated resistance of MCF7RasG12V cells to treatment with
paclitaxel, doxorubicin, and 5-fluorouracil. We first examined
whether inhibition of PI-3K with its specific inhibitor, LY294002,
enhanced the apoptosis of the MCF7RasG12V cells following
treatment with the chemotherapeutic agents. Within the dose
range from 0 to 40mM LY294002, there was an LY294002-dose-
dependent inhibition of PI-3K activity, as demonstrated by
reduced phosphorylation of Akt by Western blot analysis with
Akt serine-473 phosphorylation-specific antibodies. At the dose of
20 or 40mM, LY294002 nearly completely inhibited RasG12V-
induced PI-3K/Akt activation (Figure 3A, gels b, lanes 7 or 8 vs
lanes 1 or 2). In contrast, within the given dose range of LY294002,
there was no effect of LY294002 on the activity of the MEK/MAPK
pathway; the Ras-induced increase in MEK/MAPK activity was
unchanged (Figure 3A, gels d, lane 7 or 8 vs lanes 1 or 2),
indicating the relative specificity of LY294002 in our experimental
system in inhibiting the PI-3K/Akt pathway. We found that the
treatment of MCF7RasG12V cells with LY294002 markedly
sensitised the cells to doxorubicin-induced apoptosis (Figure 1A).
Similar enhancement of sensitivity by LY294002 was found in
MCF7RasG12V cells treated with paclitaxel or 5-fluorouracil
(Figure 4B and C).
We simultaneously examined whether inhibition of MEK with
its specific inhibitor, PD98059, would enhance apoptosis of the
MCF7RasG12V cells following treatment with the chemotherapeu-
tic agents. Similar to the specificity of inhibition of LY294002
(within the given dose range) on PI-3K, there was a PD98059-dose-
dependent inhibition of MEK activity, as demonstrated by reduced
phosphorylation of MAPK by Western blot analysis with MAPK
threonine-202 phosphorylation-specific antibodies. At doses be-
tween 40 and 80mM, PD98059 nearly completely inhibited
RasG12V-induced MEK/MAPK activation (Figure 3B, gel d, lane
7o r8vs lanes 1 or 2), but had no effect on the activity of the PI-
3K/Akt pathway. The Ras-induced increase in PI-3K/Akt activity
remained, indicating the relative specificity of PD98059 in our
experimental system in inhibiting MEK/MAPK pathways. Similar
to the results with LY294002 treatment, inhibition of the MEK/
MAPK pathway with PD98059 sensitised the MCF7RasG12V cells
to treatments with doxorubicin, paclitaxel, and 5-fluorouracil, but
it appears that, in all three cases, inhibition of PI-3K with
LY294002 is statistically more effective than inhibition of MEK in
enhancing drug-induced apoptosis (Figure 4).
Although both LY294002 and PD98059 showed relative specifi-
city in inhibiting PI-3K and MEK, respectively, there were still
possibilities that the two compounds may inhibit additional
kinases other than PI-3K or MEK. To further confirm our results
obtained with LY294002 and PD98059, we investigated whether
expression of dominant-negative (dn) PI-3K (delta p85) or dn
MEK (M97K) will have similar effects on sensitising the
MCF7RasG12V cells to the drug-induced apoptosis. Figure 5A
shows the transient expressions of dn PI-3K and dn MEK in
MCF7RasG12V cells, respectively. Compared with control-vector-
transfected cells, expression of a dn PI-3K sensitized the
MCF7RasG12V cells to doxorubicin-, paclitaxel-, and 5-fluorour-
acil-induced apoptosis, assayed by the apoptosis ELISA
(Figure 5B). In contrast, expression of a dn MEK showed different
effects: nearly no effect on doxorubicin-induced apoptosis, a slight
effect on paclitaxel-induced apoptosis, and a more apparent effect
on 5-fluorouracil-induced apoptosis. To provide an additional
assay to measure the sensitisation of dn PI-3K and dn MEK on
drug-induced apoptosis, we performed TUNEL assay (Figure 5C).
Transient expression of either dn PI-3K or dn MEK showed similar
sensitisation of paclitaxel- and 5-fluorouracil-induced apoptosis in
MCF7RasG12V cells. We were unable to detect doxorubicin-
induced apoptosis by TUNEL, possibly due to the interference of
an inherent fluorescence of doxorubicin.
DISCUSSION
The mechanism of drug resistance involves not only the delivery of
drugs into targeted cancer cells but also the ability of cancer cells
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Figure 3 Noncrossing inhibition of RasG12V-induced activation of PI-3K
and MEK by their respective specific inhibitors (PD98059 and LY294002).
MCF7RasG12V clone C cells were exposed to increasing concentrations of
PD98059 as indicated (A) or increasing concentrations of LY294002 as
indicated (B) in a medium containing 0.5% CS FBS for 16h, accompanied
by parallel cultures of parental MCF7 cells and control-vector- transfected
cells in 0.5% CS FBS medium without PD98059 or LY294002. Cells were
collected for Western blot analysis for the levels of Ras (a), phosphorylated
Akt (b), total Akt (c), phosphorylated MAPK (d), and MAPK (p42) (e).
Ras-mediated chemoresistance
W Jin et al
188
British Journal of Cancer (2003) 89(1), 185–191 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sto survive under drug challenge, which is collectively contributed
by multiple intrinsic and extrinsic factors. Recent interest and
effort in reducing the resistance of cancer cells to chemotherapy
have been focused on modulation at various levels of signalling
pathways in cancer cells. In our current study, we demonstrated an
unequal contribution of the two important Ras downstream
pathways, PI-3K and MEK/MAPK, in mediating increased drug
resistance in MCF7 human breast cancer cells following the
expression of a constitutively active Ras (H-RasG12V). This
experimental setting was undertaken to reflect not only the
oncogenic Ras mutation per se, but in a boarder sense, the Ras
protein activated by receptor tyrosine kinase-mediated signal
transduction, which is commonly seen in breast cancer. We found
that the resistance of MCF7 cells expressing H-RasG12V to the
commonly used breast cancer chemotherapeutic agents (doxor-
ubicin, paclitaxel, and 5-fluorouracil) was well correlated with
apoptosis induced by the antineoplastic agents.
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Figure 4 Enhancement of drug-induced apoptosis by the PI-3K-specific
inhibitor LY294002 and the MEK-specific inhibitor PD98059 on
MCF7RasG12V cells. MCF7RasG12V cells were cultured for a 16-h pre-
drug period with or without 20mm LY294002 or 40mm PD98059, 8-h
pulse exposure of the cells to 2.5mm doxorubicin (A), 5mm paclitaxel (B),
or 40mm 5-fluorouracil (C), and a 16-h postdrug period in 10% CS-FBS.
Cells were then harvested for apoptosis ELISA. The statistical differences
between LY294002 and PD98059 in enhancing the cytotoxicity of drugs
(doxorubicin, paclitaxel, or 5-fluorouracil) were calculated by Student’s t-
test.
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Figure 5 Effects of dn PI-3K (Dp85) and dn MEK (K97M) on Ras-
induced drug resistance. MCF7RasG12V cells were transfected with
plasmid containing HA-tagged MEK (K97M) or HA-tagged PI-3K (Dp85)
for 16h for transient expression, followed by a 8-h exposure to
doxorubicin, paclitaxel, or 5-fluorauracil, and a 16-h postdrug period in a
medium containing 10% CS FBS. The cells were then harvested for
detection of the expressions of the dn forms of PI-3K (A, gel a) or MEK (A,
gel b) by Western blot analyses with an anti-HA antibody, and for
determination of apoptosis by ELISA (B) and by TUNEL (C). The statistical
differences between the cells expressing dn PI-3K (Dp85) and dn MEK
(K97M) in enhancing the cytotoxicity of drugs (doxorubicin, paclitaxel, or
5-fluorouracil) were calculated by Student’s t-test. dn: dominant negative;
NS*¼nonspecific signals.
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sCells often receive multiple stimuli. Given the complexity of Ras-
mediated signal transduction, none of its downstream pathways
function alone. In order to develop molecular-targeted approaches
for sensitising cancer cells to chemotherapy, it is important to
elucidate the downstream pathways that play major roles in Ras-
mediated drug resistance of cancer cells to chemotherapy. The
MEK/MAPK and PI-3K pathways are at the bifurcation point of
Ras-mediated downstream pathways. Our experimental goal was to
determine whether both MEK/MAPK and PI-3K pathways
contribute to Ras-mediated drug resistance, and if so, which of
the two pathways plays a major role in mediating Ras activation-
induced drug resistance. By using both specific inhibitors and
dominant negative expression vectors of MEK or PI-3K, we found
that PI-3K seems to play a major role in drug resistance in our
experimental setting, because inhibition of PI-3K by treatment of
the cells with the PI-3K specific inhibitor LY294002 or by
expression of a dominant negative PI-3K expression vector
(Dp85) showed a statistically significant better sensitisation than
inhibition of MEK with similar approaches in MCF7RasG12V cells
following treatment with doxorubicin, paclitaxel, or 5-fluorouracil.
An important caveat is that, in our experimental setting, we
used the dose of LY294002 (20mM) that completely inhibited
Ras-mediated PI-3K activation (demonstrated by reduced phos-
phorylation of Akt to the level comparable to that in control-
vector-transfected cells, shown in Figure 3A, gel b), and that did
not affect the activity of MEK (demonstrated by unchanged
phosphorylation of MAPK, shown in Figure 3A, gels d). Similarly,
we used the dose of PD98059 (40mM) that completely inhibited the
activity of MEK without affecting the activity of PI-3K, as
demonstrated by reduced phosphorylation of MAPK to the level
comparable to that for control- vector-transfected cells and by an
unchanged level of Akt phosphorylation (shown in Figure 3B gels b
and d). This experimental condition allowed us to rule out any
potential variation that may result from insufficient or cross
inhibition of PI-3K or MEK by LY294002 or PD98059. Further-
more, because LY294002 or PD98059 may inhibit other kinases in
addition to PI-3K or MEK, we used the dominant negative
expression vectors of PI-3K and MEK, respectively, in our
experiments and obtained comparable results.
Akt is one of the major effector molecules following PI-3K
activation. Akt is activated by PDKs following its recruitment to
the cell membrane by phosphatidylinositol 3,4,5-triphosphate
(PtdIns-(3,4,5)-P3) and phosphatidylinositol 3,4-biphosphate
(PtdIns-(3,4)-P2), which are generated by PI-3K. Recent evidence
indicates that Akt is frequently activated in human breast cancer.
The activated status of Akt may lead to breast cancer patients
being more prone to relapse with distant metastasis (Perez-
Tenorio and Stal, 2002). In breast cancer, the increase in Akt
kinase activity may mainly result from the activities of Akt
upstream regulatory signals produced by overexpression or
activation of the EGF receptor family. Less commonly, it could
also result from the mutational activation of Ras oncogene that
activates Akt through the PI-3K pathway (Datta et al, 1996; Liu
et al, 1998) or from the mutational inactivation of the PTEN
tumour-suppressor gene that normally inhibits Akt activity by
dephosphorylating the PI-3,4,5-P3 and PI-3,4-P2 produced by PI-
3K (Stambolic et al, 1998; Ramaswamy et al, 1999). Although the
mechanisms have not yet been fully characterised, activated Akt
signalling is believed to promote cell survival by regulating several
key molecules that are involved in apoptosis, such as Bad (Datta
et al, 1997; del Peso et al, 1997), caspase-9 (Cardone et al, 1998),
FKHRL1 (Brunet et al, 1999), CREB (Du and Montminy, 1998), and
IKKa (Ozes et al, 1999).
Earlier observations reported that IGF-I can rescue MCF7 cells
from doxorubicin-induced apoptosis in a PI-3K-dependent, but
not MAPK-dependent manner (Gooch et al, 1999). In contrast,
IGF-I rescued MCF7 cells from paclitaxel-induced apoptosis, which
required both PI-3K and MAPK, suggesting that the drug
mechanism-specific action in IGF-I attenuated the response of
breast cancer cells to doxorubicin and paclitaxel (Gooch et al,
1999). In our experimental setting with the MCF7 cells expressing
constitutively active Ras, we found that the apoptosis induced by
paclitaxel or doxorubicin can be enhanced by inhibition of either
PI-3K or MAPK, but inhibition of the PI-3K appears to be more
effective, suggesting that both pathways are unequally involved in
rescuing the cells from drug-induced apoptosis.
In summary, our results indicate that the PI-3K pathway may
play a more important role in mediating receptor tyrosine kinase-
mediated resistance to chemotherapy and suggest that PI-3K/Akt
might be a critical target molecule for anticancer intervention in
breast cancer.
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